Shenzhen Salubris Pharmaceuticals (002294.SZ)

Executive Summary

Shenzhen Salubris Pharmaceuticals is a Chinese biopharma company with a diversified pipeline spanning cardiovascular, metabolic, and bone diseases. The company has advanced several Phase 3 programs, including SAL056 for postmenopausal osteoporosis (completed 2024) and SAL003 for hyperlipidemia (completed 2025), both near potential NDA submissions. Additionally, its renal anemia candidate Enarodustat is already approved in China, with ongoing trials for label expansion. With a strong commercial product base and a focus on innovative drugs, Salubris is positioned for near-term regulatory milestones that could drive value.

Upcoming Catalysts (preview)

• Q3 2026NDA submission for SAL056 (postmenopausal osteoporosis)80% success
• Q1 2027NDA submission for SAL003 (hyperlipidemia)75% success
• Q4 2027Phase 3 data readout for Enarodustat in renal anemia (label expansion)70% success